Health Technology Assessment (HTA) - OHE

We found for

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

News
December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Insight
December 2020

A NICE Wind of Change? The What and So What of the NICE Methods Consultation

Insight
October 2020

The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision

News
September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

News
August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

News
July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Past Event
April 2020

How Should the World Pay for a COVID-19 Vaccine?

News
April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

News
March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

News
March 2020

Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds

News
January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

News
January 2020

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions

Health Technology Assessment…

Realising the Broader Value of Vaccines in the UK

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Should We ‘Drop Dead’ from Health State Valuation?

A NICE Wind of Change? The What and So What of the NICE Methods Consultation

The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

How Should the World Pay for a COVID-19 Vaccine?

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions

Realising the Broader Value of Vaccines in the UK

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies